Dedicated to the Discovery of the Cause and Cure of Waldenström’s Macroglobulinemia

Dr. Steven Treon is the Director of the Bing Center for Waldenström’s Research and an attending physician for medical oncology, at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, in Boston, Massachusetts. He is also an Associate Professor of Medicine at Harvard Medical School in Boston, and is the Chair of the Waldenström's Macroglobulinemia Clinical Trials Group.

After earning a doctorate in tumor immunology from Boston University (BU), Dr Treon did a postgraduate fellowship in the Department of Microbiology at BU School of Medicine. Dr Treon received a medical degree from BU School of Medicine and completed an internship in medicine and a residency in internal medicine at BU Medical Center. Dr Treon also served a clinical fellowship in hematology and oncology at Mass General Hospital and a research fellowship at Dana-Farber Cancer Institute and Harvard Medical School. He received certification from the American Board of Internal Medicine in 1995, and in medical oncology in 1997.

Dr Treon’s main research interests focus on understanding the genetic basis and pathogenesis of Waldenström’s macroglobulinemia and the development of therapeutics for this malignancy. He serves on the editorial boards of the Journal of Clinical Oncology, Blood, Clinical Cancer Research, and The Lancet. Dr Treon is a member of several professional societies including the American Medical Association, American Society of Hematology, American Society of Clinical Oncology, European Society of Hematology and the Massachusetts Medical Society. He has been honored with several research and academic awards from various national and international medical foundations and institutes, including the Robert A. Kyle Award for Waldenström's Macroglobulinemia.

Click this link to download a .pdf version of Dr. Treon's CV.

NE Support Group Meeting: Feb 5, 2012, Dana-Farber Jimmy Fund Auditorium: Dr. Treon's presentation on Waldenstrom's Macroglobulinemia - Genetic Basis & Therapy. Click this link to view the lecture.

The 7th International Workshop for Waldenstrom's Macroglobulinemia and Symposium on Advances in Multiple Myeloma was held on August 23-26, 2012 at the Hyatt Regency, Goat Island, in beautiful historic Newport, Rhode Island, USA. Over 250 people attended this 4 day workshop which included 14 sessions with 60 technical presentations from 70 speakers, including 6 debates, 22 poster presentations (including 6 oral presentations), 5 presentations and 1 debate on advances in Multiple Myeloma, and 2 consensus panel discussions.

In addition to the 3-day workshop was a 4th day including the consensus panel discussions, and a 2-hour Workshop Review for Patients which included 6 comprehensive presentations covering the major topics of the previous 3 days regarding treatment options and the latest research. The Workshop Review was followed by a luncheon where attendees and faculty had a chance to dine and discuss.

IWWM-7 was our most comprehensive meeting to date, building upon all previous workshops. It reflects the continued growth in investigators working on the genetic basis, pathogenesis, and treatment of WM. Since the IWWM began in 2000, the number of participating investigators has steadily grown, as have also the number of WM related publications including those arising from the IWWM which have been published in Blood, Clinical Lymphoma Myeloma, Haematologica, Journal of Clinical Oncology, and Seminars in Oncology. A highlight of IWWM-7 was the research regarding MYD88 and its role as a major contributer to WM, and where the latest findings have been published in the August, 2012 edition of the New England Journal of Medicine.

We hope the IWWM-7 has enriched each attendees understanding of Waldenstrom's Macroglobulinemia, and will help foster discoveries leading to its cure.